Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

Autism-like phenotypes and increased NMDAR2D expression in mice with KDM5B histone lysine demethylase deficiency.

Science advances·2026
Same author

Schizophrenia risk gene ZNF804A controls ribosome localization and synaptogenesis in developing human neurons.

Science advances·2026
Same author

The prenatal sex steroid theory of autism after 25 years.

Nature human behaviour·2026
Same author

Epigenetic biomarkers in neurodegenerative diseases: from molecular signatures to therapeutic targets.

Trends in neurosciences·2026
Same author

Methylomic signatures of tau and amyloid-beta in transgenic mouse models of Alzheimer's disease neuropathology.

NPJ dementia·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Martyn Frith1, Barry Chioza1, Rosemary Bamford2

  • 1University of Exeter, Exeter, Devon, United Kingdom.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

开发一种用于检测血中神经元衍生的无细胞DNA (cfDNA) 的新型检测方法,对早期神经退行症诊断具有前途. 这种表观遗传分析方法旨在在发生不可逆转的脑损伤之前识别神经元损伤.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 基因组学就是基因组学.
  • 生物标志物发现发现

背景情况:

  • 神经退行性疾病对全球健康构成重大挑战.
  • 目前的诊断只能在不可逆转的脑损伤后检测到神经退行.
  • 对于早期检测方法来预防永久的神经缺陷,存在着未得到满足的需求.

研究的目的:

  • 开发一种基于测序的测定方法,用于检测血中使用无细胞DNA (cfDNA) 检测神经退行.
  • 利用表观遗传分析技术来识别神经元生物标记物.
  • 为了使神经退行早期检测,在显著的大脑损伤显现之前.

主要方法:

  • 从神经退行性疾病患者和对照组收集血液样本.
  • 使用纳米孔技术对cfDNA进行直接测序,用于检测表观遗传修饰.
  • 使用一种新的排名β双项 (RBB) 算法来进行神经元衍生cfDNA解卷.

主要成果:

  • 该RBB算法准确地从cfDNA数据中解构细胞类型比例,即使读取深度和cfDNA比例较低.
  • 在模拟和真实的人类血样本中检测神经元衍生cfDNA分数的高精度.
  • 预先的灵敏度和特异性分析表明,该试验有可能检测神经退行症.

结论:

  • 初步发现表明,神经元衍生cfDNA是神经退行症的一个有前途的生物标志物.
  • 需要对解卷算法进行进一步的改进.
  • 临床效用需要在较大的患者队列中进行验证.